TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11768726

Group type: EXPERIMENTAL
Intervention: metoprolol (METO)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: amlodipine (AMLO)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: temocapril (TEMO)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: doxazosin (DOXA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: trichlormethiazide (TCTZ)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: nifedipine (NIFE)
Number of subjects: 64
Study: 9246799

Group type: EXPERIMENTAL
Intervention: Quantitative urinalysis with New Use criteria
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Quantitative urinalysis and estimated New Uses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Qualitative urinalysis
Number of subjects: 42
Study: 8153735

Group type: EXPERIMENTAL
Intervention: Midnight catheter removal
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 AM catheter removal
Number of subjects: 0
Study: 2849682

Group type: EXPERIMENTAL
Intervention: Fish oil (18 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil supplement
Number of subjects: 0
Study: 31506877

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV) with a tidal volume of 6 ml/IBW and PEEP of 10 cm H2O
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional ventilation (CV) with a tidal volume of 10 ml/IBW and PEEP of 4 cm H2O
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation (LPV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 24
Study: 31203670

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 12

Group type: COMPARATOR
Intervention: Midline tendon‐split approach
Number of subjects: 12
Study: 29231549

Group type: EXPERIMENTAL
Intervention: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.2 group, 50 cases)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Conventional intravenous general anesthesia (No.1 group, 48 cases)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Acupoint transcutaneous electric stimulation combined with conventional intravenous general anesthesia (No.3 group, 48 cases)
Number of subjects: 146
Study: 26423737

Group type: EXPERIMENTAL
Intervention: Integrated management using ready-to-use therapeutic food (RUTF) with a decreasing ration and health maintenance messages.
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Standard management using fortified blended flour for MAM and RUTF for SAM.
Number of subjects: 1957

Group type: EXPERIMENTAL
Intervention: Integrated management protocol.
Number of subjects: 1957

Group type: COMPARATOR
Intervention: Standard management protocol.
Number of subjects: 1957
Study: 23549132

Group type: EXPERIMENTAL
Intervention: NeuroFlo device
Number of subjects: 192

Group type: COMPARATOR
Intervention: Best medical treatment (control)
Number of subjects: 192
Study: 21450069

Group type: EXPERIMENTAL
Intervention: Physical activity screening (alone or in combination with diet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three types of screening
Number of subjects: 0
Study: 18505968

Group type: EXPERIMENTAL
Intervention: FEC-P (fluorouracil, epirubicin, cyclophosphamide followed by weekly paclitaxel)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: FEC-P
Number of subjects: 1246

Group type: COMPARATOR
Intervention: FEC
Number of subjects: 1246
Study: 17160915

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day and 8 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 12706027

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 20
Study: 10764700

Group type: EXPERIMENTAL
Intervention: 50 U Botulinum toxin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 100 U Botulinum toxin (initial injection)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 100 U Botulinum toxin (second injection after 30 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 200 U Botulinum toxin
Number of subjects: 118
Study: 8842654

Group type: EXPERIMENTAL
Intervention: Xylitol (0.25 g kg‐1 h‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (0.5 g h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 30
Study: 1569343

Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acid treatment of plasma
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2411876

Group type: COMPARATOR
Intervention: No speech therapy
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Porch Index of Communicative Ability test score at 4 weeks
Number of subjects: 52
Study: 29017742

Group type: EXPERIMENTAL
Intervention: Preoperative anterior thigh temperature
Number of subjects: 46
Study: 26569427

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 81

Group type: COMPARATOR
Intervention: Neuromuscular protocol adherence
Number of subjects: 81
Study: 24401754

Group type: EXPERIMENTAL
Intervention: 60 000IU vitamin D orally once a week for 10 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: 600 000IU single intramuscular injection
Number of subjects: 61
Study: 23140417

Group type: EXPERIMENTAL
Intervention: Menaquinone-4 (MK-4) 420 μg (945 nmol) single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 420 μg (647 nmol) single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menaquinone-4 (MK-4) 60 μg (135 nmol) consecutive administration for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) 60 μg (92 nmol) consecutive administration for 7 days
Number of subjects: 0
Study: 20361620

Group type: EXPERIMENTAL
Intervention: Extended preoperative course of radiotherapy plus 5-fluorouracil chemomodification (group 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Extended preoperative course of radiotherapy plus 5-fluorouracil chemomodification and hyperthermia (group 2)
Number of subjects: 62
Study: 17373916

Group type: EXPERIMENTAL
Intervention: Rifaximin 1600 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rifaximin 1200 mg/day
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 16378561

Group type: EXPERIMENTAL
Intervention: Fusidic acid gel 1% (one drop, four times daily for one week)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (one drop, four times daily for one week)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fusidic acid gel 1%
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 12212881

Group type: EXPERIMENTAL
Intervention: Regular Coke
Number of subjects: 17

Group type: COMPARATOR
Intervention: Diet Coke
Number of subjects: 17
Study: 9527749

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anaesthesia with 8 mg of hyperbaric bupivacaine 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined sciatico‐femoral nerve block with 7 mg kg(‐1) of mepivacaine 2%
Number of subjects: 20
Study: 10150352

Group type: EXPERIMENTAL
Intervention: Adhesive-sparing moisturizing cream, 0.1 mL applied to gloves
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no cream)
Number of subjects: 48
Study: 2673080

Group type: EXPERIMENTAL
Intervention: Dried chopped feverfew (70‐86 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 41
Study: 1067276

Group type: EXPERIMENTAL
Intervention: Interspace brush
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inter-Dens
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Waxed dental floss
Number of subjects: 35
Study: 30431649

Group type: EXPERIMENTAL
Intervention: Alliance and Rupture Observation Scale (AROS)
Number of subjects: 0
Study: 28698476

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 26110982

Group type: EXPERIMENTAL
Intervention: Cueing approach
Number of subjects: 31

Group type: COMPARATOR
Intervention: Recasting approach
Number of subjects: 31
Study: 24105072

Group type: EXPERIMENTAL
Intervention: 20 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 μg ethinyl-estradiol (EE) with 3 mg drospirenone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (20 μg EE and 30 μg EE)
Number of subjects: 30
Study: 21777734

Group type: EXPERIMENTAL
Intervention: CERTIFECT™ (fipronil, amitraz, and (S)-methoprene)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 16
Study: 20439553

Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ) 480 mL daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Substitute grape-flavored drink (SGD) 480 mL daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: No beverage (NTG)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ)
Number of subjects: 76
Study: 17255252

Group type: EXPERIMENTAL
Intervention: NaDCC tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14999359

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (660 mg daily, 440 mg for patients ≥65 years)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acetaminophen (4000 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11682416

Group type: EXPERIMENTAL
Intervention: Tramadol 0.5 mg/kg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amitriptyline 15 or 20 mg
Number of subjects: 45
Study: 9458416

Group type: EXPERIMENTAL
Intervention: Pacemaker activated pacing
Number of subjects: 83

Group type: COMPARATOR
Intervention: Pacemaker inactivated pacing
Number of subjects: 83
Study: 7948797

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine (0.2 mg/kg) and scopolamine (0.01 mg/kg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.75 mg/kg)
Number of subjects: 44
Study: 3283766

Group type: EXPERIMENTAL
Intervention: Combination therapy with Flutamide and LHRH agonist [D‐Trp]LHRH ethylamide
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combination therapy with Flutamide
Number of subjects: 363
Study: 30106600

Group type: EXPERIMENTAL
Intervention: Clavicular hook plate (cHP)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Double double-button suture (dDBS)
Number of subjects: 73
Study: 26858013

Group type: EXPERIMENTAL
Intervention: Wii-Fit balance-based video games training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional balance training (control group)
Number of subjects: 30
Study: 24236573

Group type: EXPERIMENTAL
Intervention: All meal provision for 12 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Self-directed diet for 12 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: All meal provision after self-directed diet
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Meal provision for a total of 24 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Groups switching diets
Number of subjects: 85
Study: 23327968

Group type: EXPERIMENTAL
Intervention: Carbonated Water (CW)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 19
Study: 20820150

Group type: EXPERIMENTAL
Intervention: Premedication consisting of 7.5 mg midazolam, 50 mg diclofenac, 1000 mg acetaminophen (orally) and fentanyl (intravenously)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 209
Study: 19026887

Group type: EXPERIMENTAL
Intervention: Laser activation using conical‐ended optical fibers with Er:YAG and Er,Cr:YSGG lasers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conical fibers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Er:YAG and Er,Cr:YSGG lasers
Number of subjects: 0
Study: 16602172

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 6
Study: 11817992

Group type: EXPERIMENTAL
Intervention: Low dose polyethylene glycol 3350 plus electrolytes (PEG+E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PEG+E
Number of subjects: 0
Study: 10632776

Group type: EXPERIMENTAL
Intervention: finasteride 5 mg daily for 24 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo daily for 24 months
Number of subjects: 28
Study: 7793211

Group type: EXPERIMENTAL
Intervention: Therapeutic suggestion (reassuring information focused on minimising postoperative nausea and vomiting)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Blank tape (control group)
Number of subjects: 70
Study: 2019938

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (0.10 mg/kg in 2 ml 0.9% saline solution)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 83

Group type: COMPARATOR
Intervention: 0.9% saline solution placebo
Number of subjects: 83
Study: 6814298

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (IV NTG) 0.5 micrograms/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (IV NTG) 0.1 micrograms/kg/min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30765737

Group type: EXPERIMENTAL
Intervention: DHA-CHO-VE multivitamin treatment (DHA, choline, vitamin E)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHA-VD multivitamin treatment (DHA, vitamin D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 30
Study: 30541606

Group type: EXPERIMENTAL
Intervention: 8 mg lidocaine + 2 mg CPC
Number of subjects: 250

Group type: COMPARATOR
Intervention: 1 mg lidocaine + 2 mg CPC
Number of subjects: 250
Study: 27026311

Group type: EXPERIMENTAL
Intervention: 35 Gy to prostate (4-mm PTV margin)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 40 Gy to prostate (5-mm PTV margin)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: 40 Gy to prostate/seminal vesicles (5-mm PTV margin)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rectal V38 (≥2.0 cm³)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Use of anticoagulants
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Presence of hemorrhoids
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Rectal V38 < 2.0 cm³ with anticoagulants or V38 ≥ 2.0 cm³ plus 1 other risk factor
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall incidence of HH
Number of subjects: 258
Study: 23825002

Group type: EXPERIMENTAL
Intervention: Exercise during bed rest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0
Study: 22272750

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (oral treatment for four weeks)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 20023363

Group type: EXPERIMENTAL
Intervention: 12 week multicomponent exercise training program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 34
Study: 17405894

Group type: EXPERIMENTAL
Intervention: Molecular profiling for breast cancer management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic risk factors alone
Number of subjects: 0
Study: 16181615

Group type: EXPERIMENTAL
Intervention: 100 microg selenium/d
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 200 microg selenium/d
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: 300 microg selenium/d
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study: 14687380

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 351

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g once a day
Number of subjects: 351
Study: 10955752

Group type: EXPERIMENTAL
Intervention: Regular inhaled terbutaline (500-1000 microg four times daily)
Number of subjects: 52
Study: 8832859

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional plain film radiography (CPF)
Number of subjects: 52
Study: 1614781

Group type: EXPERIMENTAL
Intervention: Rice, beans, and vegetable oil (group RB)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rice, soy-protein isolate, corn syrup solids, and vegetable oil (group RS)
Number of subjects: 46
Study: 6146499

Group type: EXPERIMENTAL
Intervention: Propranolol (four times a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nadolol (once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31206571

Group type: EXPERIMENTAL
Intervention: Pulpectomy treatment with Maisto‐Capurro paste (G1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment with 3Mix‐MP paste (G2)
Number of subjects: 46
Study: 29676928

Group type: EXPERIMENTAL
Intervention: Reflexology applied 2 days a week for 3 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 64
Study: 27559969

Group type: EXPERIMENTAL
Intervention: High self-mastery (measured by Pearlin mastery score)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Frailty (defined by modified Fried criteria)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Functional decline
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Interaction between frailty and mastery
Number of subjects: 715
Study: 24520674

Group type: EXPERIMENTAL
Intervention: Yuleshu oral mixture combined with conventional therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 88
Study: 23006807

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 20422846

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 90
Study: 17239325

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (progressive muscle relaxation training and systematic desensitization)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐hydroxytryptamine type 3 receptor antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complementary and alternative methods (acupuncture and acupressure)
Number of subjects: 0
Study: 16139580

Group type: EXPERIMENTAL
Intervention: Active Vagus Nerve Stimulation (VNS)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 235
Study: 12130963

Group type: EXPERIMENTAL
Intervention: Automatic tube compensation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Continuous positive airway pressure
Number of subjects: 21
Study: 10428520

Group type: EXPERIMENTAL
Intervention: Clindamycin 2% vaginal cream
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 168
Study: 7498208

Group type: EXPERIMENTAL
Intervention: Prolonged sequential inflations (3 to 5 inflations of 3 to 5 min each, total duration > or = 12 min, group 1, n = 20 lesions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard sequential inflations (3 to 5 inflations of < or = 1 min each, total duration < or = 3 min, group 2, n = 24 lesions)
Number of subjects: 41
Study: 2188696

Group type: EXPERIMENTAL
Intervention: Day patient treatment
Number of subjects: 89

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 89
Study: 7040497

Group type: EXPERIMENTAL
Intervention: Bumetanide (0.5 mg intravenous)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Furosemide (20 mg intravenous)
Number of subjects: 20
Study: 30447172

Group type: EXPERIMENTAL
Intervention: Jaw Functional Limitation Scale (JFLS)
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Dental status stratified norms
Number of subjects: 1372
Study: 28404973

Group type: EXPERIMENTAL
Intervention: L-asparaginase, cisplatin, etoposide, and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT)
Number of subjects: 66
Study: 25692329

Group type: EXPERIMENTAL
Intervention: Fibre Retention Osseous Resective Surgery (FibReORS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Osseous Resective Surgery (ORS)
Number of subjects: 30
Study: 24339273

Group type: EXPERIMENTAL
Intervention: Group Training (GT) of the Otago Exercise Program (OEP) performed twice weekly for 12 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Group Training (GT) of the Otago Exercise Program (OEP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Home Training (HT) of the Otago Exercise Program (OEP) performed three times a week for 12 weeks
Number of subjects: 125

Group type: COMPARATOR
Intervention: Home Training (HT) of the Otago Exercise Program (OEP)
Number of subjects: 125
Study: 23326865

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perindopril (5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Perindopril (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19236441

Group type: EXPERIMENTAL
Intervention: Insulin injection into normal tissue
Number of subjects: 8

Group type: COMPARATOR
Intervention: Insulin injection into lipohypertrophic tissue
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGMS) profiles for normal tissue
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous glucose monitoring (CGMS) profiles for lipohypertrophic tissue
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Injection sites (normal vs lipohypertrophic)
Number of subjects: 8
Study: 17589370

Group type: EXPERIMENTAL
Intervention: Marijuana (3.9% THC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dronabinol (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Marijuana (2.0% THC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10